Leading by example

Evolution

2016

Advancing oncology portfolio

With the addition of GBR 1372, a bispecific monoclonal antibody from Glenmark’s BEAT® technology platform, Glenmark has three clinical candidates for various types of cancer in its pipeline.

2016

Providing differentiated generics products

Glenmark launched ezetimibe, the first and only generic version of Zetia® in the United States, for the treatment of high cholesterol.

2015

Making respiratory a focus area

Glenmark announced a Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe and received approval for generic Seretide in Russia.

2014

Expanded manufacturing operations – US and Switzerland

Glenmark commissioned a new manufacturing facility in North Carolina, US for the development of injectable and oral solid dosages.

Glenmark also set up a new antibody manufacturing facility in La Chaux-de-Fonds, Switzerland to develop clinical GMP-grade biologics for clinical trials.

2012

Out-licensing deal with Forest Labs

Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitors. Glenmark received USD 15 Mn payment from Forest Labs under an option agreement.

2011

Out-licensing of first novel biological entity GBR 500

  • Glenmark out-licensed its first novel biological entity GBR 500 to Sanofi-Aventis and received an upfront payment of USD 50 Mn and a milestone payment of USD 5 Mn in May 2014

2010

Out-licensing deal for its first-in-class molecule GRC 15300

Glenmark entered into an out-licensing deal with Sanofi-Aventis for its molecule GRC 15300, a first-in-class TRPV3 antagonist, and received an upfront payment of USD 25 million.

2007

Out-licensing deal with Eli Lilly

Eli Lilly acquired the rights to Glenmark's portfolio of TRPV1 antagonist molecules.Glenmark received an upfront fee of USD 45 Mn

2006

Commenced research in novel biologics

To focus on the development of novel biologics, Glenmark established its first R&D center for New Biological Entity research in Switzerland.

Glenmark entered into an out-licensing deal with Merck KGaA for its molecule melogliptin and received a total payment of USD 31 million.

2005

Expanded operations in the US market

Glenmark launched front-end commercial sales in the US in 2005. To support its US operations with high quality products, it set up a manufacturing facility built to US FDA specifications in Goa, India.

2005

Out-licensing deal for novel molecule Oglemilast

Glenmark entered into a deal with Teijin Pharma for the Japan rights of its molecule oglemilast for which it received an upfront payment of USD 6 Mn.

2004

Glenmark’s first out-licensing deal

Glenmark created history when it sealed its first out-licensing deal with Forest Laboratories for GRC 3886. Glenmark received USD 35Mn as upfront and milestone payments

2001

Diversified into API manufacturing

Glenmark forayed into the manufacturing of active pharmaceutical ingredients (API) at its facility in Kurkumbh, Maharashtra. In the following year, Glenmark also acquired an API manufacturing facility in Ankleshwar, Gujarat.

2000

Adding value to our stakeholders

Glenmark listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) of India at a market capitalization of $40 million.

1999

Glenmark commissioned the Sinnar R&D center in Maharashtra

1979

The first success

Glenmark entered the dermatology market with the launch of ‘Candid cream.’

Even today, dermatology is a key focus area for Glenmark in generics as well as novel drug discovery..

1977

Touching lives of patients for over three decades

Glenmark was established in 1977 by our Founder Emeritus Late Mr. Gracias Saldanha.